These findings suggest that understanding the intricate regulatory networks involving METTL3, BRD4, and HSP47 may provide valuable insights into the molecular underpinnings of GC and potentially reveal novel therapeutic targets. This evidence concerns the gene BRD4 and gastric cancer.